(19) World Intellectual Property Organization International Bureau





(43) International Publication Date 14 October 2004 (14.10.2004)

PCT

(10) International Publication Number WO 2004/087766 A3

(51) International Patent Classification⁷: C12N 15/62

C07K 19/00,

(21) International Application Number:

PCT/IB2004/001049

(22) International Filing Date: 5 April 2004 (05.04.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/460,490

4 April 2003 (04.04.2003) US

- (71) Applicant (for all designated States except US): UNI-VERSITE DE LAUSANNE [CH/CH]; Rue du Bugnon 21, CH-1005 Lausannne (CH).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): DEPERTHES, David [FR/CH]; Chemin de Varmey 15A, CH-1299 Crans-Pres-Celigny (CH). CLOUTIER, Sylvain [CA/CH]; Chemin de Boissonnet 63, CH-1010 Lausanne (CH). MACH, Jean-Pierre [CH/CH]; Avenue de

Valmont 18, CH-1010 Lausanne (CH). HOLLER, Nils [DE/CH]; Sunnhale 6, CH-3271 Radelfingen b. Aarberg (CH). FATTAH, Omar [LB/CH]; Grand-rue 9, CH-1183 Bursins (CH).

- (74) Agent: KATZAROV S.A.; 19, rue des Epinettes, CH-1227 Genève (CH).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK,

[Continued on next page]

(54) Title: PEPTABODY FOR CANCER TREATMENT

P-EGF EARLES hGGMP Hinge 80 a.a

Amino acid sequence of peptabody Irrelevant:
MYSFEDLHHHHHHGDLGPQMLRELQETNAALQDVRDYLRQLVREITFLKN
TVMECDACGMQQTSPPTPPTPSPSTPPTPSPRS*

Amino acid sequence of peptabody EGF:
MYSFEDLHHHHHHGDLGPQMLRELQETNAALQDVRDYLRQLVREITFLKN
TVMECDACGMQQTSPPTPPTPSPSTPPTPSPRSNSDSECPLSHDGHCLH
DGVCMYIEALDKYACNCVVGYIGERCQYRDLKWWELR*

(57) Abstract: The present invention relates to an isolated and recombinant fusion peptabody, which binds to a member of the epidermal growth factor receptor useful in inhibiting the growth of certain tumor cells. Also disclosed are, nucleic acids encoding said isolated and recombinant fusion peptabody, kits and pharmaceutical compositions comprising said isolated and recombinant fusion peptabody as an active substance. Finally, a method for the manufacture of said isolated and recombinant fusion peptabody, and its use for the preparation of a medicament for the treatment or prevention of cancer are provided.

WO 2004/087766 A3



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:

— of inventorship (Rule 4.17(iv)) for US only

Published:

with international search report

- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report: 16 December 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

enternational Application No
PCT/IB2004/001049

Α.	CLASSIFI	CATION OF	SUBJECT	MATTER	
TF	PC 7	C07K19	a/00	C12N1	5/62

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, BIOSIS, WPI Data, PAJ, EMBASE, CHEM ABS Data

C. DOCUM	ENTS CONSIDERED TO BE RELEVANT			
Category °	Citation of document, with indication, where appropriate, of the	elevant passages	1,5-7, 11,12, 17-23, 25, 27-30, 35,36,39	
X	HOUIMEL MEHDI ET AL: "Selection peptides and synthesis of pentam peptabody molecules reacting spential with ErbB-2 receptor" INTERNATIONAL JOURNAL OF CANCER vol. 92, no. 5, 1 June 2001 (2004) pages 748-755, XP009034136 ISSN: 0020-7136 the whole document	meric ecifically		
		-/		
X Furt	her documents are listed in the continuation of box C.	X Palent family members are listed	In annex.	
"A" docum consider "E" earlier filing of "L" docum which citatio 'O' docum other 'P" docum later t	ategories of cited documents: ent defining the general state of the art which is not deced to be of particular relevance document but published on or after the international state ent which may throw doubts on priority claim(s) or is cited to establish the publication date of another in or other special reason (as specified) ent referring to an oral disclosure, use, exhibition or means ent published prior to the international filling date but han the priority date claimed	 "T" tater document published after the Interior priority date and not in conflict with cited to understand the principle or the invention "X" document of particular relevance; the cannot be considered novel or cannot involve an inventive step when the document of particular relevance; the cannot be considered to involve an indocument is combined with one or ments, such combined with one or ments, such combination being obvion the art. "&" document member of the same patent 	the application but early underlying the claimed invention to considered to comment is taken alone claimed invention wentive step when the one other such docu-us to a person skilled family	
	7 September 2004	0 6. 10. 04		
Name and	mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl. Fax: (+31-70) 340-3016	Authorized officer Valcarcel, R		

International Application No

		TCT/IB2004/001049		
(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT				
Category •	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
X	DEPERTHES DAVID LUC ET AL: "Effect of peptabody anti Epidermal Growth Factor receptors on prostate cancer cell lines proliferation" EUROPEAN UROLOGY SUPPLEMENTS, vol. 1, no. 1, January 2002 (2002-01), page 31, XP009034146 & XVIITH CONGRESS OF THE EUROPEAN ASSOCIATION OF UROLOGY; BIRMINGHAM, ENGLAND, UK; FEBRUARY 23-26, 2002 ISSN: 1569-9056	1-7,10, 11, 17-23, 25, 27-30, 35,36,39		
Υ	the whole document	1-44		
A	CAMPBELL I D ET AL: "STRUCTURE-FUNCTION RELATIONSHIPS IN EPIDERMAL GROWTH FACTOR EGF AND TRANSFORMING GROWTH FACTOR-ALPHA TGF-ALPHA" BIOCHEMICAL PHARMACOLOGY, vol. 40, no. 1, 1990, pages 35-40, XP002289670 & FOURTH BIOCHEMICAL PHARMACOLOGY SYMPOSIUM ON NMR METHODS FOR ELUCIDATING MACROMOLECULE-LIGAND INTERA ISSN: 0006-2952 cited in the application the whole document	1-44		
A	STORTELERS CATELIJNE ET AL: "Epidermal growth factor contains both positive and negative determinants for interaction with ErbB-2/ErbB-3 heterodimers" BIOCHEMISTRY, vol. 41, no. 13, 2 April 2002 (2002-04-02), pages 4292-4301, XP002289671 ISSN: 0006-2960 cited in the application the whole document	1-44		
Y	LEHTO V-P: "EGF receptor: which way to go?" FEBS LETTERS, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 491, no. 1-2, 23 February 2001 (2001-02-23), pages 1-3, XP004257261 ISSN: 0014-5793 page 2	1-44		

International Application No

C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	ROSE KEITH ET AL: "Polyethyleneglycol-based chains of precise length for chemobodies" PEPTIDES FOR THE NEW MILLENNIUM KLUWER ACADEMIC PUBLISHERS, 3300 AA, DORDRECHT, NETHERLANDS; KLUWER ACADEMIC PUBLISHERS, 101 PHILLIP DRIVE, ASSINIPPI PARK, NORWELL, MA, 02061, USA, 2000, pages 47-49, XP009034147 & 16TH AMERICAN PEPTIDE SYMPOSIUM; MINNEAPOLIS, MI, USA; JUNE 26-JULY 01, 1999 ISSN: 0-7923-6445-7 the whole document	1-44
Y	WO 98/18943 A (CIBA GEIGY AG ; KAJAVA ANDREY (CH); UNIV LAUSANNE (CH); CRAMERI RETO () 7 May 1998 (1998-05-07) the whole document	1-44
Y	GARIEPY J ET AL: "Vectorial delivery of macromolecules into cells using peptide-based vehicles" TRENDS IN BIOTECHNOLOGY, ELSEVIER, AMSTERDAM,, GB, vol. 19, no. 1, 1 January 2001 (2001-01-01), pages 21-28, XP004227647 ISSN: 0167-7799 See in particular paregraphbridging pages 23 and 24.	1-44
Y	NOMIZU MOTOYOSHI ET AL: "Multimeric forms of Tyr-Ile-Gly-Ser-Arg (YIGSR) peptide enhance the inhibition of tumor growth and metastasis" CANCER RESEARCH, vol. 53, no. 15, 1993, pages 3459-3461, XP001182805 ISSN: 0008-5472 the whole document	1-44
Y	US 6 350 860 B1 (SABLON ERWIN ET AL) 26 February 2002 (2002-02-26) the whole document	1-44
Α	US 6 348 568 B1 (ANWER MOHMED K ET AL) 19 February 2002 (2002-02-19) the whole document	8,45
A	WO 02/066628 A (AVENTIS PHARMA GMBH) 29 August 2002 (2002-08-29) the whole document	8,45

International Application No TCT/IB2004/001049

	-C1/1B2004/001049		
	Delevent to etc.		
Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.		
US 5 571 507 A (BACH JEAN-FRANCOIS ET AL) 5 November 1996 (1996-11-05) the whole document	13-15		
WO 02/06469 A (COCO WAYNE M; ENCELL LANCE P (US); ARENSDORF JOSEPH J (US); ENCHIRA B) 24 January 2002 (2002-01-24) SEQ ID NO: 17	1-44		
CARAGLIA M ET AL: "EGF activates an inducible survival response via the RASfwdarwErk-1/2 pathway to counteract interferon-alpha-mediated apoptosis in epidermoid cancer cells." CELL DEATH AND DIFFERENTIATION, vol. 10, no. 2, February 2003 (2003-02), pages 218-229, XP009034327 ISSN: 1350-9047 the whole document	1-44		
MURAYAMA YOICHI: "High concentration of epidermal growth factor induces apoptosis in breast and esophageal cancer cells transplanted into nude mice" ONCOLOGY REPORTS, vol. 1, no. 6, 1994, pages 1055-1062, XP009034329 the whole document	1-44		
WO 94/18345 A (AFFYMAX TECH NV; UNIV LELAND STANFORD JUNIOR (US)) 18 August 1994 (1994-08-18) page 49	45		
GENNITY J ET AL: "SIGNAL PEPTIDE MUTANTS OF ESCHERICHIA COLI" JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, PLENUM PUBLISHING, NEW YORK, NY, US, vol. 22, no. 3, June 1990 (1990-06), pages 233-269, XP009025834 ISSN: 0145-479X the whole document	45		
	·		
	the whole document WO 02/06469 A (COCO WAYNE M; ENCELL LANCE P (US); ARENSDORF JOSEPH J (US); ENCHIRA B) 24 January 2002 (2002-01-24) SEQ ID NO: 17 CARAGLIA M ET AL: "EGF activates an inducible survival response via the RASfwdarwErk-1/2 pathway to counteract interferon-alpha-mediated apoptosis in epidermoid cancer cells." CELL DEATH AND DIFFERENTIATION, vol. 10, no. 2, February 2003 (2003-02), pages 218-229, XP009034327 ISSN: 1350-9047 the whole document MURAYAMA YOICHI: "High concentration of epidermal growth factor induces apoptosis in breast and esophageal cancer cells transplanted into nude mice" ONCOLOGY REPORTS, vol. 1, no. 6, 1994, pages 1055-1062, XP009034329 the whole document WO 94/18345 A (AFFYMAX TECH NV; UNIV LELAND STANFORD JUNIOR (US)) 18 August 1994 (1994-08-18) page 49 GENNITY J ET AL: "SIGNAL PEPTIDE MUTANTS OF ESCHERICHIA COLI" JOURNAL OF BIOENERGETICS AND BIOMEMBRANES, PLENUM PUBLISHING, NEW YORK, NY, US, vol. 22, no. 3, June 1990 (1990-06), pages 233-269, XP009025834 ISSN: 0145-479X		

Information on patent family members

International Application No
TCT/IB2004/001049

Patent document Sited in search report		Publication date		Patent family member(s)		Publication date
			A11			22-05-1998
WO 9818943	Α	07-05-1998	AU	6909298 <i>l</i> 9818943 <i>l</i>		07-05-1998
			WO	0938571		01-09-1999
			EP 	U9365/1 /		01-09-1999
US 6350860	B1	26-02-2002	AU	9262598		08-03-1999
			CA	2297692		25-02-1999
			WO	9909055		25-02-1999
			ΕP	1015480		05-07-2000
			US	2003099648	Al 	29-05-2003
US 6348568	B1	19-02-2002	US	6258782	B1	10-07-2001
	•		US	6656906	B1	02-12-2003
			US	2003186874		02-10-2003
			AU	766995	B2	30-10 - 2003
			AU	4194999		06-12-1999
			CA	2332338		25-11-1999
			CN	1310626	T	29-08-2001
			EP	1079846	A1	07-03-2001
			HR	20000789	A1	30-06-2001
			HU	0101826	A2	28-09-2001
			ID	29141	Α	02-08-2001
			JP	2002515449		28-05-2002
			NO	20005836		19-01-2001
			NZ	508352		27-02-2004
			PL	344342		05-11-2001
			TR	200100163		21-06-2001
			WO	9959615	A1	25-11-1999
			US	6562787		13-05-2003
•			ZA	200006642	Α ·	28-05-2001
WO 02066628	Α	29-08-2002	DE	10108100	A 1	29-08-2002
			BR	0207385	Α	10-02-2004
			CA	2438935	A1	29-08-2002
			WO	02066628	A2	29-08-2002
			EP	1364030		26-11-2003
			JP	2004518442		24-06-2004
			NO	20033671		17-10-2003
			US	2003028001	A1	06-02-2003
US 5571507	Α	05-11-1996	AU	3730093	A	13-09-1993
			CA	2130182		02-09-1993
			EP	0630383		28-12-1994
			JP	7507541		24-08-1995
			WO	9317038	A1	02-09-1993
WO 0206469	A	24-01-2002	AU	7355901	Α	30-01-2002
			WO	0206469		24-01-2002
WO 9418345	Α	18-08-1994	US	5512435	Α	30-04-1996
	••		ΑÜ	6171194		29-08-1994
			WO	9418345		18-08-1994